[HTML] thelancet.com

[HTML][HTML] The conundrum of interleukin-6 blockade in COVID-19

C Campochiaro, L Dagna - The Lancet Rheumatology, 2020 - thelancet.com
Since the very first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection were identified in China, patients with severe manifestations of COVID-19 have …
被引用次数：38 相关文章

[引用][C] The conundrum of interleukin-6 blockade in COVID-19

C Campochiaro, L Dagna - THE LANCET. RHEUMATOLOGY, 2020 - iris.unisr.it
The conundrum of interleukin-6 blockade in COVID-19 IRIS IRIS Home Sfoglia
Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano English English …

[引用][C] The conundrum of interleukin-6 blockade in COVID-19

C Campochiaro, L Dagna - The Lancet Rheumatology, 2020 - cir.nii.ac.jp
The conundrum of interleukin-6 blockade in COVID-19 | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …

[引用][C] The conundrum of interleukin-6 blockade in COVID-19

C Campochiaro, L Dagna - The Lancet. Rheumatology, 2020 - pubmed.ncbi.nlm.nih.gov
[HTML] nih.gov

[HTML][HTML] The conundrum of interleukin-6 blockade in COVID-19

C Campochiaro, L Dagna - The Lancet. Rheumatology, 2020 - ncbi.nlm.nih.gov
Since the very first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection were identified in China, patients with severe manifestations of COVID-19 have …

The conundrum of interleukin-6 blockade in COVID-19.

C Campochiaro, L Dagna - The Lancet. Rheumatology, 2020 - europepmc.org
Since the very first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection were identified in China, patients with severe manifestations of COVID-19 have …

[引用][C] The conundrum of interleukin-6 blockade in COVID-19

C Campochiaro, L Dagna - The Lancet. Rheumatology, 2020 - pubmed.ncbi.nlm.nih.gov